Dornelles L N, Pereira-Ferrari L, Messias-Reason I
Immunopathology Laboratory and Department of Medical Pathology, Federal University of Paraná, Curitiba, Brazil.
Clin Exp Immunol. 2006 Sep;145(3):463-8. doi: 10.1111/j.1365-2249.2006.03161.x.
Mannan-binding lectin (MBL) is an important component of the first-line defence against infections. Evidence has shown that MBL deficiency, reducing phagocytosis and internalization of intracellular pathogens may protect the host against intracellular infections such as leprosy. In this study, we speculated whether genetically determined low MBL serum levels confer protection against Mycobacterium leprae infection. One hundred and ninety-one patients with leprosy, presenting lepromatous (n = 118), tuberculoid (n = 31), dimorph (n = 30) and indeterminate (n = 12) clinical forms and 110 healthy controls matched with the patients according to sex, age and ethnic background were investigated. MBL concentrations were measured in a double-antibody enzyme immune assay and C-reactive protein (CRP) serum levels by nephelometry. A significant negative association of MBL low values (< 100 ng/ml) was observed with lepromatous patients when comparing with controls and tuberculoid patients [10/118, 8.47%versus 21/110, 19.09%P = 0.03 chi(2) with Yates' correction, odds ratio (OR) 0.39, confidence interval (CI) 0.18-0.88 and 8/31, 25.81%, P = 0.02, OR 0.27, CI 0.09-0.75, respectively]. There was no significant difference in the distribution of MBL levels between patients and controls or among the clinical forms. The concentration of CRP was significantly increased in the patients (P = 0.0002) and in the lepromatous form (P = 0.0001) when compared to controls. A weak positive correlation between MBL and CRP levels was observed in the patients (P = 0.010, R = 0.255). These data suggest a protective role for MBL deficiency against the development of the most severe and multi-bacillary form of leprosy.
甘露聚糖结合凝集素(MBL)是抗感染一线防御的重要组成部分。有证据表明,MBL缺乏会降低细胞内病原体的吞噬作用和内化,这可能保护宿主免受麻风病等细胞内感染。在本研究中,我们推测基因决定的低MBL血清水平是否能提供针对麻风分枝杆菌感染的保护作用。我们调查了191例麻风病患者,他们呈现瘤型(n = 118)、结核样型(n = 31)、中间界线类偏瘤型(n = 30)和未定类(n = 12)临床类型,并根据性别、年龄和种族背景选取了110名与患者匹配的健康对照。采用双抗体酶免疫测定法测量MBL浓度,用散射比浊法测量血清C反应蛋白(CRP)水平。与对照组和结核样型患者相比,瘤型患者中观察到MBL低值(< 100 ng/ml)存在显著负相关[10/118,8.47% 对21/110,19.09%,经Yates校正的χ²检验P = 0.03,比值比(OR)0.39,置信区间(CI)0.18 - 0.88;以及8/31,25.81%,P = 0.02,OR 0.27,CI 0.09 - 0.75]。患者与对照组之间或各临床类型之间MBL水平分布无显著差异。与对照组相比,患者组(P = 0.0002)及瘤型患者(P = 0.0001)的CRP浓度显著升高。在患者中观察到MBL与CRP水平呈弱正相关(P = 0.010,R = 0.255)。这些数据表明MBL缺乏对最严重的多菌型麻风病的发展具有保护作用。